Vontobel Holding Ltd. Buys 36,085 Shares of HealthEquity, Inc. (NASDAQ:HQY)

Vontobel Holding Ltd. raised its stake in HealthEquity, Inc. (NASDAQ:HQY) by 96.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 73,564 shares of the company’s stock after buying an additional 36,085 shares during the period. Vontobel Holding Ltd.’s holdings in HealthEquity were worth $4,877,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. McGlone Suttner Wealth Management Inc. bought a new stake in shares of HealthEquity in the 4th quarter valued at about $29,000. DekaBank Deutsche Girozentrale bought a new stake in shares of HealthEquity during the 3rd quarter valued at about $41,000. Lazard Asset Management LLC boosted its position in shares of HealthEquity by 117.9% during the 3rd quarter. Lazard Asset Management LLC now owns 549 shares of the company’s stock valued at $40,000 after purchasing an additional 297 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of HealthEquity by 36.5% during the 3rd quarter. Fifth Third Bancorp now owns 602 shares of the company’s stock valued at $44,000 after purchasing an additional 161 shares in the last quarter. Finally, Operose Advisors LLC bought a new stake in shares of HealthEquity during the 3rd quarter valued at about $44,000. Institutional investors own 99.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on HQY. Barclays upped their target price on HealthEquity from $84.00 to $104.00 and gave the company an “overweight” rating in a research report on Friday, February 23rd. JMP Securities began coverage on HealthEquity in a research report on Thursday, April 4th. They set a “mkt outperform” rating and a $101.00 target price on the stock. Bank of America increased their price target on HealthEquity from $93.00 to $97.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. BTIG Research increased their price target on HealthEquity from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, March 20th. Finally, KeyCorp increased their price target on HealthEquity from $85.00 to $95.00 and gave the stock an “overweight” rating in a report on Friday, March 22nd. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating to the stock. Based on data from MarketBeat.com, HealthEquity currently has a consensus rating of “Moderate Buy” and an average target price of $96.17.

HealthEquity Stock Performance

Shares of HealthEquity stock opened at $79.87 on Thursday. The company has a market cap of $6.85 billion, a PE ratio of 124.80, a price-to-earnings-growth ratio of 1.31 and a beta of 0.53. HealthEquity, Inc. has a 52 week low of $48.86 and a 52 week high of $84.49. The business has a 50 day moving average price of $81.02 and a 200-day moving average price of $74.17. The company has a quick ratio of 4.76, a current ratio of 4.76 and a debt-to-equity ratio of 0.43.

HealthEquity (NASDAQ:HQY) last issued its quarterly earnings results on Tuesday, March 19th. The company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.42 by $0.08. The company had revenue of $262.39 million during the quarter, compared to the consensus estimate of $258.56 million. HealthEquity had a return on equity of 6.91% and a net margin of 5.57%. Equities analysts anticipate that HealthEquity, Inc. will post 2.12 earnings per share for the current fiscal year.

Insider Activity at HealthEquity

In related news, EVP Delano Ladd sold 2,558 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $82.59, for a total transaction of $211,265.22. Following the completion of the sale, the executive vice president now directly owns 47,438 shares of the company’s stock, valued at $3,917,904.42. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other HealthEquity news, Director Evelyn S. Dilsaver sold 32,500 shares of the business’s stock in a transaction on Tuesday, March 26th. The stock was sold at an average price of $79.29, for a total value of $2,576,925.00. Following the sale, the director now directly owns 32,123 shares in the company, valued at $2,547,032.67. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Delano Ladd sold 2,558 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $82.59, for a total value of $211,265.22. Following the completion of the sale, the executive vice president now owns 47,438 shares in the company, valued at $3,917,904.42. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,322 shares of company stock valued at $5,682,895. 2.70% of the stock is owned by insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.